Experimental CAR t therapy takes on tough leukemia

NCT ID NCT07347418

Recruiting now Disease control Sponsor: University of Colorado, Denver Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This early-phase trial tests a new treatment called CD64 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack leukemia cells. The main goals are to check safety and find the best dose, with 23 participants expected to enroll.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD64 CAR T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for patients with hard-to-treat acute myeloid leukemia.
What could go wrong: This is a very early Phase 1 trial with only 23 participants, so it may not show strong benefits. There are also risks of serious side effects from the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOID LEUKEMIA) HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS) MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC SYNDROME (MDS)/AML REFRACTORY ACUTE MYELOID LEUKEMIA (AML) RELAPSED ACUTE MYELOID LEUKEMIA (AML)

Contacts and locations

Locations

University of Colorado Hospital
RECRUITING

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.